PRESS RELEASE: Potential new drug found for schizophrenia

Potential new drug found for schizophrenia

PITTSBURGH, Sept. 24 U.S. researchers have developed a drug that promises to treat the cognitive deficits associated with schizophrenia.

The scientists said the hallucinations, delusions and emotional deficits that are features of schizophrenia can be treated by existing medicines. However, they said those medicines have limited effects on the impaired attention, memory and problem-solving that comprise the cognitive deficits of schizophrenia.

University of Pittsburgh Professor Bita Moghaddam and colleagues at the Institute for Neurodegenerative Disorders in New Haven, Conn., investigated various compounds that affect brain cells in the prefrontal cortex and hippocampus by using the chemical glutamate as a neurotransmitter.

They succeeded in identifying a specific drug that affects glutamate receptors and reverses chemically induced abnormalities in prefrontal cortical functioning.

Moghaddam said the drug "has a normalizing effect on the spontaneous activity of prefrontal cortex neurons" and the work might lead to development of drugs designed to selectively treat the cognitive deficits of schizophrenia.

The research is to be published in the journal Biological Psychiatry.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.